On November 6, 2023 XNK Therapeutics AB ("XNK") reported that it will participate in the SITC (Free SITC Whitepaper) meeting, which takes place in San Diego, USA, and present the latest research relating to the company’s leading natural killer (NK) cell therapies (Press release, XNK Therapeutics, NOV 6, 2023, View Source [SID1234637071]). Two abstracts have been accepted for presentation at the meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first poster, titled Harnessing the Potential of Autologous NK Cells for Immune Therapy of Patients with Advanced Bladder Cancer, describes the successful expansion of autologous NK cells from peripheral blood mononuclear cells (PBMCs) from bladder cancer patients. Results demonstrate that NK cells from patients before and after first line platinum-based chemotherapy can be expanded and activated ex vivo to become cytotoxic against tumor cells.
The second poster, titled Feeder-free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment, describes the successful expansion and activation of autologous NK cells from PBMCs of diverse cohorts of patients with Acute Myeloid Leukemia (AML).
XNK will be represented at the meeting by Chief Scientific Officer Dr. Anna-Karin Maltais.
The data have been generated in collaboration with XNK’s external partners, Dr. Anders Ullén and Dr. Fernanda Costa Svedman at the Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, for the bladder cancer study, and Dr. Abhishek Maiti and Dr. Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract.